MedTrace Logo

A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

NCT00144495 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2009-02-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effectiveness and safety of recombinant human erythropoietin in anemic cancer patients undergoing chemotherapy.

Conditions

  • Chemotherapy Induced Anemia

Interventions

DRUG

recombinant human erythropoietin

3600IU(s.c.)/week for 7 weeks and 54000IU(s.c.)/week for 5 weeks

DRUG

recombinant human erythropoietin

36000IU(s.c.)/week for 12 weeks

Sponsors & Collaborators

  • Chugai Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Yoshiharu Ishikura · Chugai Pharmaceutical

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2004-11-30
Completion
2005-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00144495 on ClinicalTrials.gov